Jack T Brown

This paper computationally designs thermostable miniproteins that neutralize Nipah and Hendra viruses with subnanomolar affinity and potent in vitro antiviral activity.

The paper shows repeated SARS-CoV-2 vaccine boosters elicit variant-specific memory B cells and neutralizing antibodies, suggesting immune imprinting can be overcome with updated vaccines.

This paper describes a miniprotein inhibitor that neutralizes multiple SARS-CoV-2 variants and protects mice against them when administered post-exposure.

This study designs miniproteins that inhibit MERS-CoV by targeting the spike protein, showing broad neutralization and protective efficacy in mice.

This study identifies a potent monoclonal antibody, MARV16, that broadly neutralizes Marburg virus and related viruses, with a cryo-EM structure revealing its mechanism of action.

This paper designs multivalent RBD nanoparticle vaccines that overcome immune imprinting and provide broad protection against SARS-CoV-2 variants and sarbecoviruses.

This study shows SARS-CoV-2 nsp1 inhibits translation in bat cells and human cells, revealing its broad activity across mammals.

This study uses deep mutational scanning to analyze how mutations in the Nipah virus receptor-binding protein affect function, receptor binding, and antibody escape, revealing constrained regions and limited antigenic variation in natural strains.

HKU5 merbecoviruses use bat Pipistrellus abramus ACE2 and several artiodactyl ACE2s through a cryo-EM-defined binding mode distinct from other ACE2-using coronaviruses, showing independent evolution of ACE2 usage.

This study develops MERS-CoV vaccines using a protein nanoparticle platform, showing they induce strong neutralizing antibodies and protect mice against MERS-CoV challenge.

The paper isolates two human monoclonal antibodies that broadly neutralize PDCoV variants and identifies their mechanism of action.

This study identifies molecular mechanisms of FCoV-23 pathogenicity, including receptor usage and biotype switching, and identifies a cross-reactive antibody for therapeutic development.